Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Amphastar Pharmaceuticals (AMPH) .Amphastar currently has an average broke ...

Drug stock Amphastar Pharmaceuticals (AMPH) has formed a cup base and settled down after a steep sell-off in January. Now, as an IBD Sector Leader, Amphastar stock is about 18% off its all-time high.X Amphastar develops injectable, inhalation and intranasal medical and insulin products. Its products are used mainly in hospitals and urgent care clinics. It also makes over-the-counter asthma inhaler Primatene Mist, along with emergency glucagon treatment kits for low blood sugar.Amphastar ranks No. 1 among 75 ...

Company Performance - Amphastar Pharmaceuticals (AMPH) closed at $55.61, with a daily increase of +1.85%, outperforming the S&P 500's gain of 0.57% [1] - Over the past month, AMPH shares gained 1.05%, lagging behind the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% [1] - The upcoming EPS for Amphastar is projected at $0.87, indicating a 19.18% increase year-over-year, while revenue is estimated at $174.9 million, reflecting a 29.54% increase compared to the same quarter last year [1] Analyst Estimates - Recent changes to analyst estimates for Amphastar Pharmaceuticals reflect shifting business dynamics, with positive adjustments indicating a favorable outlook on the company's health and profitability [2] - The Zacks Rank system, which incorporates estimate changes, currently ranks Amphastar at 3 (Hold), with the consensus EPS estimate remaining unchanged over the last 30 days [2] Valuation Metrics - Amphastar Pharmaceuticals has a Forward P/E ratio of 14.47, which aligns with the industry's Forward P/E of 14.47 [3] - The company has a PEG ratio of 0.64, compared to the Medical - Generic Drugs industry's average PEG ratio of 1.33 [3] - The Medical - Generic Drugs industry holds a Zacks Industry Rank of 169, placing it in the bottom 33% of over 250 industries [3]

The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.Nkarta (NKTX) ...

Amphastar Pharmaceuticals (AMPH) closed at $54.94 in the latest trading session, marking a -0.81% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.06%. At the same time, the Dow added 0.35%, and the tech-heavy Nasdaq lost 0.76%.Shares of the specialty pharmaceutical company witnessed a loss of 10.45% over the previous month, trailing the performance of the Medical sector with its gain of 1.65% and the S&P 500's gain of 3.36%.Analysts and investors alike will be keepi ...

The U.S. economy showed robustness in 2023 while expanding at a healthy pace in the final three months and squashing recession fearmongering. The domestic economy displayed astounding resilience in the face of the Federal Reserve’s monetary tightening campaign to tame relentless price pressures. It continued to thrive, banking on the uptick in consumer outlays and strength in the labor market.The U.S. economy accelerated at an annualized rate of 3.3% in the final quarter of 2023, more than economists’ forec ...

Toward the end of 2023, the economy started showing signs of stabilization and easing inflationary pressure as the Fed finally decided to keep interest rates unchanged. This is likely to benefit generic drugmakers like Amphastar Pharmaceuticals (AMPH) , Teva Pharmaceutical (TEVA) and Dr. Reddy’s Laboratories (RDY) , who can potentially benefit from declining costs in the long run.These drugmakers are also focusing on new product launches or existing products with high gross margins to support their top and ...

Investors seeking healthy returns should add stocks with favorable liquidity to their portfolios.Liquidity measures a company’s capability to meet its short-term debt obligations. Stocks with high liquidity levels have always been in demand, owing to their potential to provide maximum returns.Investors should be alert before considering such stocks. While a high liquidity level may imply that the company is clearing its dues faster than its peers, it may also suggest that it cannot utilize assets competentl ...

The most recent trading session ended with Amphastar Pharmaceuticals (AMPH) standing at $54.03, reflecting a -1.44% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 0.07%.Prior to today's trading, shares of the specialty pharmaceutical company had lost 11.19% over the past month. This has lagged the Medical sector's gain of 7.37% and the S&P 500's gain of 3.98% in that time.Market participants will be closely following the financial results of Amphastar Pharmace ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Dan Dischner - SVP of Corporate Communications Bill Peters - CFO Conference Call Participants Glen Santangelo - Jefferies Tim Chiang - Capital One Operator Greetings and welcome to the Amphastar Pharmaceuticals Third Quarter Earnings Conference Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, in ...